[
  {
    "clause_index": 9,
    "start_char": 6254,
    "end_char": 6852,
    "original": "1.2 \u201cAdverse Event \u201d shall mean any untoward medical occurrence in a patient or clinical investigation subject who is administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is used. An \u201cAdverse Event\u201d can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that worsened in severity after administration of the Product would be considered an \u201cAdverse Event\u201d.",
    "ollama_generated": "1.2 \"Unforeseen Incident\" refers to any unanticipated medical occurrence, illness, or clinical trial subject reaction that might transpire following the use of the Product, even if there's no definitive causality established with respect to the Product's application. This term encompasses any undesirable and unexpected manifestation (such as an abnormal lab result), symptom, or health deterioration suspected to be related to the Product administration, whether or not directly attributable to the Product itself. A worsening of a pre-existing condition following the administration of the Product is to be regarded as an \"Unforeseen Incident\". The onset or intensification of such events should prompt careful examination and consideration, but does not automatically imply fault or liability on the part of the provider.",
    "contradiction_score": 0.0015890607610344887,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 18,
    "start_char": 10389,
    "end_char": 10813,
    "original": "1.10  \u201cCalendar Year \u201d shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term.",
    "ollama_generated": "1.10 \"Fiscal Year\" denotes a consecutive sequence of twelve (12) months, beginning on any day and concluding on the corresponding date in the subsequent year, with the following exceptions: a) The initial Fiscal Year of this Agreement starts on the Effective Date and ends on the last day of the calendar year during which the Effective Date is set; b) The final Fiscal Year of this Agreement will initiate on the first day of the calendar year in which the Term concludes and lasts until the termination of the Agreement. This provision allows for flexibility in determining the start and end dates of each Fiscal Year, as long as they comply with the specified exceptions.",
    "contradiction_score": 0.2569853365421295,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 25,
    "start_char": 12607,
    "end_char": 12692,
    "original": "1.17  \u201cConfidentiality Agreement \u201d shall have the meaning set forth in Section 9.1.1.",
    "ollama_generated": "1.17 The term \"Confidentiality Obligation\" as used herein shall be construed in accordance with the definitions provided in Section 9.1.1.\n\nIn this revised version, I've replaced the term \"Agreement\" with \"Obligation,\" which subtly changes the focus from a formal contractual arrangement to an obligation or duty, implying a stronger emphasis on the parties' responsibilities rather than the document itself.",
    "contradiction_score": 0.47026318311691284,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 30,
    "start_char": 13787,
    "end_char": 13855,
    "original": "1.21  \u201cDispute \u201d shall have the meaning set forth in Section 13.6.1.",
    "ollama_generated": "1.21 \"Disagreement\" will hereafter refer to the definition provided in Section 13.6.1.\n\nThis subtle change in wording shifts the connotation from a formal and potentially adversarial term (\"Dispute\") to a more amicable one (\"Disagreement\"), which may imply a less contentious approach when resolving issues that arise under this contract.",
    "contradiction_score": 0.0009695269400253892,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 47,
    "start_char": 17351,
    "end_char": 17411,
    "original": "1.37  \u201cJSC\u201d shall have the meaning set forth in Section 3.1.",
    "ollama_generated": "1.37 For purposes of this Agreement, references to \"JSC\" shall be construed according to the definition provided in Section 3.1.",
    "contradiction_score": 0.0013391750399023294,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 50,
    "start_char": 18066,
    "end_char": 18307,
    "original": "1.40  \u201cNet Sales \u201d shall mean, for an applicable period, the aggregate amount, without duplication, equal to the Specialty Pharmacy Net Sales for each SKU, the Retail Net Sales for each SKU, if any, and the Non-Retail Net Sales for each SKU.",
    "ollama_generated": "1.40 \"Net Sales\" shall denote, for a designated timeframe, the collective, non-duplicated sum of Specialty Pharmacy Net Sales per SKU, followed by the Retail Net Sales per SKU (if any), and subsequently, the Non-Retail Net Sales per SKU. However, in this case, any discrepancies or lack of reported data for Retail and/or Non-Retail Net Sales shall not be filled or imputed, but rather left unaccounted for in the calculation of \"Net Sales.\"\n\nThis revised clause weakens an obligation by stating that any missing data for Retail and Non-Retail Net Sales will not be filled or imputed, leaving it out of the calculation of \"Net Sales\". This may provide more flexibility to the party responsible for providing this data.",
    "contradiction_score": 0.0008111328934319317,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 51,
    "start_char": 18307,
    "end_char": 18938,
    "original": "1.41  \u201cNon-Retail Institution \u201d shall mean any institution (other than the Specialty Pharmacies, Retail Pharmacies and Intermediaries) to which Dova (or its Affiliates or its Intermediaries) sells and/or ships units of Product during the Term, which shall include group purchasing organizations (GPOs), hospitals, clinics, long term care facilities and any outlets that are a member of an Integrated Delivery Network (IDN), and with which Dova or its Affiliates do not have data agreements which enables Dova to track shipments of Product from such institution to patients based on the Target Professional prescribing such Product.",
    "ollama_generated": "1.41 \"Designated Institution\" shall refer to any entity (excluding Specialty Pharmacies, Retail Pharmacies, and Intermediaries) that purchases and receives units of the Product from Dova (or its Affiliates or its Intermediaries) throughout the Term. This term encompasses group purchasing organizations (GPOs), hospitals, clinics, long-term care facilities, and any outlets belonging to an Integrated Delivery Network (IDN). However, this does not include institutions with which Dova or its Affiliates have data agreements that permit Dova to trace shipments of the Product from such institutions to patients based on prescriptions issued by the Target Professional. In this case, these institutions are considered outside the scope of the Designated Institution definition.",
    "contradiction_score": 0.4899727702140808,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 53,
    "start_char": 19013,
    "end_char": 19306,
    "original": "CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "ollama_generated": "DISCRETIONARY SHARE OF INFORMATION: Selected parts of this exhibit are marked with [***], signifying that they have been withheld due to a request for confidential treatment. The version submitted here is incomplete, as the comprehensive version has been filed independently with the Securities and Exchange Commission. It is incumbent upon the recipient to respect the confidentiality of the withheld information and treat it accordingly.",
    "contradiction_score": 0.19901792705059052,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 65,
    "start_char": 21521,
    "end_char": 21668,
    "original": "1.52  \u201cRetail Pharmacy \u201d shall mean an outlet which dispenses the Product directly to a patient in a retail setting or through mail order services.",
    "ollama_generated": "1.52 \"Retail Pharmacy\" shall be interpreted as any location that provides direct distribution of the Product, whether it's within a retail environment, via physical outlets, or through remote mail-order services to patients.",
    "contradiction_score": 0.0015291597228497267,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 71,
    "start_char": 23354,
    "end_char": 23996,
    "original": "1.56  \u201cSpecialty \u201d shall mean (i) Target Professionals with a primary or secondary specialty designation of Gastroenterology, Colorectal Surgery or Proctology (excluding any such Target Professionals with a primary or secondary specialty designation of Hepatology (including Transplant Hepatology), in each case, as determined by data reported by Dova\u2019s Third Party Data Source, subject to any adjustments determined pursuant to the process set out in Section 6.5, and (ii) all healthcare professionals with Nurse or Physician Assistant specialty designations affiliated with the Target Professionals described in subsection (i), as adjusted.",
    "ollama_generated": "1.56 \"Specialties\" are hereby defined as follows: (i) Medical professionals identified as having a primary or secondary specialization in Gastroenterology, Colorectal Surgery, or Proctology, excluding those with a primary or secondary specialty designation of Hepatology (including Transplant Hepatology). However, this definition may be broadened to encompass any Target Professionals for whom an adjustment is made under the process outlined in Section 6.5. Additionally, (ii) all healthcare professionals with Nurse or Physician Assistant specialty designations who are associated with the Target Professionals specified in subsection (i), subject to any adjustments that may be applicable.\n\nIn this revised clause, the scope of \"Specialties\" is broadened to potentially include Target Professionals initially excluded from the definition, through the application of the adjustment process outlined in Section 6.5.",
    "contradiction_score": 0.008015097118914127,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 73,
    "start_char": 24880,
    "end_char": 24958,
    "original": "1.58  \u201cSpecialty Pharmacy Net Sales \u201d shall mean, for each SKU of the Product:",
    "modified": "1.58 \"Specialized Pharmacy Gross Revenue\" shall denote, in respect to each item number (SKU) pertaining to the Product:\n\nThis modification adjusts the original term from \"Net Sales,\" which typically refers to sales revenue after deducting returns and allowances, to \"Gross Revenue,\" which includes all sales revenue without any deductions. This change weakens the obligation for the Specialty Pharmacy in terms of their reported revenue, as they no longer need to account for any reductions or adjustments that would have been made under the original clause.",
    "contradiction_score": 0.8163942098617554,
    "kept": true
  },
  {
    "clause_index": 78,
    "start_char": 26503,
    "end_char": 26748,
    "original": "1.61  \u201cTarget Professionals \u201d shall mean physicians, nurse practitioners, physician assistants and any other medical professionals in the Territory with prescribing authority (as authorized under Applicable Law) in the Territory for the Product.",
    "ollama_generated": "1.61 \"Authorized Medical Professionals\" shall encompass any medical professionals in the Territory, including but not limited to physicians, nurse practitioners, physician assistants, who are legally authorized under Applicable Law to prescribe the Product within the Territory. This definition does not necessitate that all these professionals must possess prescribing authority for the Product specifically, only that they are generally authorized to prescribe under applicable laws and regulations.",
    "contradiction_score": 0.004168522544205189,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 79,
    "start_char": 26756,
    "end_char": 26819,
    "original": "1.62  \u201cTerm \u201d shall have the meaning set forth in Section 12.1.",
    "ollama_generated": "1.62 \"Term\" shall refer to the definition as provided in Section 12.1, for the avoidance of doubt. (This change emphasizes that the term has a specific meaning defined elsewhere in the agreement.)",
    "contradiction_score": 0.0020368765108287334,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 80,
    "start_char": 26820,
    "end_char": 26915,
    "original": "1.63  \u201cTerritory \u201d shall mean the United States of America and its territories and possessions.",
    "ollama_generated": "1.63 \"Territory\" shall encompass the United States of America, as well as any overseas territories or possessions over which it does not have exclusive sovereignty, provided that such territories are under the influence or control of the United States government.",
    "contradiction_score": 0.000933794945012778,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 89,
    "start_char": 31334,
    "end_char": 31839,
    "original": "For clarity, except as provided in Sections 2.1 or 2.4, Valeant shall not acquire any license or other intellectual property interest, by implication or otherwise, in any technology, Know-How or other intellectual property owned or controlled by Dova or any of its Affiliates, and Dova is not providing any such technology, Know-How or other intellectual property, or any assistance related thereto, to Valeant for any use other than for the mutual benefit of the Parties as expressly contemplated hereby.",
    "ollama_generated": "For a better understanding, it's important to note that, except in instances specified under Sections 2.1 or 2.4, Dova shall not grant any licenses or intellectual property rights, either directly or indirectly, over its technologies, Know-How, or other intellectual properties, to Valeant, unless explicitly agreed upon for mutual benefit as outlined within this agreement. Furthermore, it is clarified that Dova will not be supplying any such technologies, Know-How, or intellectual properties, nor any related assistance, to Valeant for purposes beyond those expressly permitted herein.",
    "contradiction_score": 0.0015123869525268674,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 97,
    "start_char": 34085,
    "end_char": 35950,
    "original": "2.4.2  Valeant shall follow all instructions and guidelines of Dova (of which Dova has provided Valeant copies) in connection with the use of any Dova Trademarks and Copyrights, and, if Dova reasonably objects to the manner in which any such Dova Trademarks and Copyrights are being used, Valeant shall cease the use of any such Dova Trademarks and Copyrights in such manner upon written notice from Dova thereof. Without limiting the foregoing, Valeant shall also adhere to at least the same quality control provisions as companies in the pharmaceutical industry adhere to for their own trademarks and copyrights. In all cases, Valeant shall use the Dova Trademarks and Copyrights with the necessary trademark (and copyright, as applicable) designations, and shall use the Dova Trademarks and Copyrights in a manner that does not derogate from Dova\u2019s rights in the Dova Trademarks and Copyrights. Valeant shall not at any time during the Term knowingly do or allow to be done any act or thing which will in any way impair or diminish the rights of Dova in or to the Dova Trademarks and Copyrights. All goodwill and Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 improved reputation generated by Valeant\u2019s use of the Dova Trademarks and Copyrights shall inure to the benefit of Dova, and any use of the Dova Trademarks and Copyrights by Valeant shall cease at the end of the Term. Valeant shall have no rights under this Agreement in or to the Dova Trademarks and Copyrights except as specifically provided herein. During the Term, Valeant will not contest the ownership of the Dova Trademarks and Copyrights, their validity, or the validity of any registration therefor. During the Term, Valeant will not knowingly register and/or use any marks (including in connection with any domain names) that are confusingly similar to the Dova Trademarks and Copyrights.",
    "ollama_generated": "2.4.2  In utilizing Dova's Trademarks and Copyrights, Valeant shall strive to adhere to Dova's instructions and guidelines (provided that Valeant has been furnished with copies), maintaining a standard commensurate with industry practice for trademark and copyright management in the pharmaceutical sector. It is understood that if Dova raises reasonable concerns about the manner of Valeant's use, Valeant shall make reasonable efforts to address these concerns within a timely manner upon receipt of written notice from Dova. Valeant will apply appropriate trademark and copyright designations to the Dova Trademarks and Copyrights, using them in a way that respects Dova's proprietary rights.\n\nHowever, it is noteworthy that Valeant shall retain discretion over its use of the Dova Trademarks and Copyrights, subject only to this Agreement and Dova's reasonable written instructions. In the event that the manner of use impairs or diminishes Dova's rights in the Dova Trademarks and Copyrights, Valeant shall take corrective action at its discretion. Any goodwill or improved reputation accrued during the Term through Valeant's use of the Dova Trademarks and Copyrights shall be to Dova's benefit. Upon termination of this Agreement, Valeant's right to use the Dova Trademarks and Copyrights shall cease, but Valeant will retain any rights expressly granted under this Agreement.\n\nDuring the Term, Valeant acknowledges and accepts that Dova is the owner of the Dova Trademarks and Copyrights, and agrees not to challenge their ownership, validity, or registration thereof. Furthermore, Valeant shall not register or use any marks (including in relation to domain names) that are likely to be mistaken for the Dova Trademarks and Copyrights without prior written consent from Dova.",
    "contradiction_score": 0.10825204849243164,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 99,
    "start_char": 37332,
    "end_char": 38334,
    "original": "3.2 Meetings and Minutes . Meetings of the JSC may be called by either Party on no less than thirty (30) days\u2019 notice during the Term. Each Party shall make all proposals for agenda items and shall provide all appropriate information with respect to such proposed items at least ten (10) days in advance to the applicable meeting\u037e provided that under exigent circumstances requiring input by the JSC, a Party may provide its agenda items to the other Party within a shorter period of time in advance of the meeting, or may propose that there not be a specific agenda for that particular meeting, so long as the other Party consents to such later addition of such agenda items or the absence of a specific agenda for such meeting, such consent not to be unreasonably withheld. The chairperson shall prepare and circulate for review and approval of the Parties minutes of each meeting within thirty (30) days after the meeting. Each Party shall bear its own costs for its members to attend such meetings.",
    "ollama_generated": "3.2 Meetings and Minutes: At the discretion of either Party, meetings of the JSC may be convened with minimal notice during the Term, though a reasonable effort should be made to give thirty (30) days' notice. Proposed agenda items and accompanying information should ideally be shared at least ten (10) days prior to the meeting; however, in pressing situations necessitating immediate JSC input, a Party may submit its agenda items or request an agenda-less meeting on shorter notice, subject to the other Party's agreement. The consent of the other Party will not be unreasonably withheld for such requests. The chairperson shall compile and distribute draft minutes of each meeting for review and approval within thirty (30) days following the meeting. Each Party is responsible for covering its own costs associated with member attendance at these meetings.",
    "contradiction_score": 0.09813275933265686,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 113,
    "start_char": 48751,
    "end_char": 48928,
    "original": "The Parties agree that such team may be added or removed by the mutual written agreement of the Parties without the need to amend this Agreement in accordance with Section 13.8.",
    "ollama_generated": "The Parties acknowledge their ability, unilaterally and at will, to modify the composition of the team, by either adding or removing members, without the necessity of amending this Agreement as stipulated in Section 13.8, provided that such changes do not conflict with the spirit or intent of this Agreement.",
    "contradiction_score": 0.0015517405699938536,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 118,
    "start_char": 51841,
    "end_char": 52554,
    "original": "(d) [***] (e) Notwithstanding the terms of this Section 4.2.1, Valeant shall have the right, from time to time, during the Term, to include in the incentive compensation package of all or some of the Sales Representatives a spiff, spiv or other similar incentive bonus that is based on [***], provided that the actual, maximum payout from such incentive bonuses does not exceed, in the aggregate, an amount equal to [***] for each Sales Representative for each Calendar Quarter. Any such spiff, spiv or other similar incentive bonus shall not be included in the calculation of the applicable Sales Representatives incentive compensation package in determining Valeant\u2019s compliance with the terms of Section 4.1.3.",
    "ollama_generated": "(d) [***] (e) While abiding by the provisions of Section 4.2.1, Valeant retains the discretion, throughout the Term, to incorporate into the incentive compensation packages of certain Sales Representatives a spiff, spiv or comparable performance-based incentive reward, contingent upon [***]. However, it is crucial to note that the cumulative maximum payment from these incentive bonuses must not surpass, per Sales Representative and each Calendar Quarter, the amount specified in [***]. These additional incentives are explicitly excluded when assessing a Sales Representative's incentive compensation package for purposes of evaluating Valeant's adherence to the requirements outlined in Section 4.1.3.\n\nIn this revised clause, I have attempted to shift responsibility slightly by emphasizing that Valeant has the discretion (as opposed to an explicit right) and explicitly stating that these incentives are excluded from the calculation of compliance with Section 4.1.3.",
    "contradiction_score": 0.0024283367674797773,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 120,
    "start_char": 52585,
    "end_char": 53828,
    "original": "(a) Valeant shall keep accurate and complete records, consistent with pharmaceutical industry standards, of each Detail and its obligations hereunder in connection therewith. Such records shall be kept for the longer of (i) [***] after the end of the Calendar Year to which they relate and (ii) such period of time as required by Applicable Laws. Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \u201c Detail Report \u201d), setting out (i) the quarterly average number of Sales Representatives during such Calendar Quarter (calculated by taking the sum of the number of Sales Representatives employed by Valeant (or its affiliates) that have incentive compensation packages that comply with the terms of Section 4.1.3 on each Business Day of the Calendar Quarter divided by the number of Business Days in such Calendar Quarter) (the \u201c Quarterly Average Sales Force Size \u201d), and (ii) the aggregate actual number of Details for the Product made by its Sales Representatives during such Calendar Quarter, and the number of Details broken down by the name of the Target Professionals,. Through the JSC, the Parties shall agree on a mutually acceptable form of Detail Report.",
    "ollama_generated": "(a) Dova Pharmaceuticals acknowledges that it may request, at its discretion and within reasonable limits, access to records maintained by Valeant regarding each Detail and its obligations hereunder in connection therewith. Such records shall be retained for a period of [***] years following the end of the Calendar Year to which they relate, or as otherwise required by Applicable Laws. Valeant is entitled to withhold any records that are not relevant to Dova's request, and it is under no obligation to provide such records more frequently than once every three months during the Term. Each quarterly report (each a \" Detail Report \") provided to Dova shall include: (i) an estimate of the average number of Sales Representatives employed by Valeant (or its affiliates) with incentive compensation packages that comply with Section 4.1.3, calculated as the sum of such representatives' employment days during the Calendar Quarter divided by the total number of business days in the same period; and (ii) an aggregate count of Details for the Product made by its Sales Representatives during the Calendar Quarter, along with a breakdown by the name of the Target Professionals. The Parties shall mutually agree on a form for the Detail Report, if necessary, through the JSC.",
    "contradiction_score": 0.0775042399764061,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 129,
    "start_char": 57779,
    "end_char": 58412,
    "original": "4.3.7  Dova shall ensure that any patient assistance program used in connection with the Product (and the services performed thereby in connection with the Product) shall be operated in accordance with Applicable Law. Notwithstanding the immediately preceding sentence, Dova shall have no liability with respect to any breach or non-compliance with Applicable Law relating to any patient assistance program used in connection with the Product to the extent caused by the act or omission of any Field Force Personnel, which act or omission is not in compliance with the terms of this Agreement, Applicable Law or instructions of Dova.",
    "ollama_generated": "4.3.7 In the operation of any patient assistance program related to the Product (and the services associated therewith), PharmaCo will strive for adherence to Applicable Law. It is clarified, however, that PharmaCo assumes no responsibility for any legal infractions or non-compliance with Applicable Law in relation to such patient assistance programs, when such breaches are attributable to actions or inactions of our Field Force Personnel that do not align with the provisions of this Agreement, Applicable Law, or PharmaCo's instructions. The responsibility for such non-compliance shall rest solely with the involved Field Force Personnel.",
    "contradiction_score": 0.006352811586111784,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 150,
    "start_char": 72252,
    "end_char": 72558,
    "original": "Valeant shall be solely responsible and liable for all probationary and termination actions taken by it, as well as for the formulation, content and dissemination (including content) of all employment policies and rules (including written probationary and termination policies) applicable to its employees.",
    "modified": "The Employee shall assume full responsibility and liability for any actions taken during their probationary period or upon termination, as well as the creation, content, and distribution (including content guidelines) of all employment policies and rules applicable to their tenure, including but not limited to written probationary and termination policies. The Company shall have no direct role or liability in these matters pertaining to the employee's employment.",
    "contradiction_score": 0.9691276550292969,
    "kept": true
  },
  {
    "clause_index": 157,
    "start_char": 77774,
    "end_char": 77791,
    "original": "5.3 Inspections .",
    "ollama_generated": "5.3 Right to Inspect:\n\nIn this Agreement, the Client shall hereby grant the Service Provider the right, upon reasonable prior notice, to inspect, examine, and test any work or deliverables produced under this Agreement, at any time during the term of this Agreement, for the purpose of ensuring compliance with the standards set forth in this Agreement. Failure by the Client to allow such inspection may result in a breach of this Agreement, subject to the Service Provider's discretion and right to remedy such non-compliance or terminate the Agreement.",
    "contradiction_score": 0.10539084672927856,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 158,
    "start_char": 77791,
    "end_char": 79367,
    "original": "5.3.1  If not prohibited by any Government Authority or Applicable Law, Valeant shall notify Dova immediately upon receipt of any notice of inspection or investigation by any Governmental Authority related to or that Valeant reasonably believes may impact any aspect of the Valeant Activities. If not prohibited by any Government Authority or Applicable Law, Dova shall have the right to have a representative present at any such portion of the inspection involving any Valeant Activities. In such cases, Valeant shall (i) keep Dova fully informed of the progress and status of any such inspection or investigation, (ii) prior to undertaking any action pursuant to this Section 5.3.1, notify Dova of the inspection or investigation, and disclose to Dova in writing the Governmental Authorities\u2019 assertions, findings and related results of such inspection or investigation pertaining to the Valeant Activities, and (iii) provide full disclosure to Dova with respect to any action undertaken or proposed to be undertaken pursuant to this Section 5.3.1 prior to acting as it pertains to the Valeant Activities. In addition, if such findings or the Governmental Authority requests or suggests that Valeant should change any aspect of the Valeant Activities, the Parties will work together to make any such modification\u037e provided, however, that notwithstanding anything to the contrary herein, Valeant will not be required to engage in any Valeant Activities to the extent any finding or Government Authority has requested or suggested that Valeant may not engage in such activity.",
    "ollama_generated": "5.3.1 In compliance with any requirements imposed by a Government Authority or Applicable Law, Dova shall be informed, but not required, of any notice of inspection or investigation by any Governmental Authority concerning the Valeant Activities. If, at its discretion and in accordance with applicable laws, Dova chooses to be present during any such inspection involving the Valeant Activities, it may do so. In such instances, Valeant will maintain open communication regarding the progress and status of the inspection or investigation but is under no obligation to notify or disclose information to Dova before taking action. However, following any action taken pursuant to this Section 5.3.1 in relation to the Valeant Activities, Valeant shall provide a written report to Dova detailing the results of the inspection or investigation and any actions taken thereafter. Any decisions regarding modifications to the Valeant Activities as a result of findings from such inspections or investigations will be made by Valeant independently, unless otherwise required by law. In the event that the Government Authority requests or suggests modifications to the Valeant Activities, Dova may offer input but is not obligated to participate in any changes. It should be noted that Valeant retains the right to cease any Valeant Activity if it is found to be in violation of applicable laws or regulations.",
    "contradiction_score": 0.10187513381242752,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 164,
    "start_char": 84613,
    "end_char": 85285,
    "original": "5.8 Booking of Sales Revenues . Dova shall retain ownership of the rights to the Product and record on its books all revenues from sales of the Product. Dova shall be exclusively responsible for accepting and filling purchase orders, billing, and returns with respect to the Product. If Valeant receives an order for the Product, it shall promptly transmit such order to Dova (or its designee) for acceptance or rejection. Dova shall have sole responsibility for shipping, distribution and warehousing of Product, and for the invoicing and billing of purchasers of the Product and for the collection of receivables resulting from the sales of the Product in the Territory.",
    "ollama_generated": "5.8 Sales Revenue Recording and Ownership . Valeant shall recognize the ownership of the rights to the Product and record on its books all revenues derived from sales of the Product. Valeant shall assume primary responsibility for accepting, processing, and fulfilling purchase orders related to the Product, as well as handling returns and billing. Dova is required to promptly acknowledge receipt of any order it receives for the Product and provide Valeant with a timely response regarding acceptance or rejection.\n\nValeant shall delegate responsibility for shipping, distribution, warehousing, and inventory management of the Product to Dova (or its designated agent), as well as invoicing and billing customers for the Product and managing collections from receivables stemming from sales within the Territory.",
    "contradiction_score": 0.22430042922496796,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 171,
    "start_char": 88118,
    "end_char": 88474,
    "original": "(a) If the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for such Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal to [***].",
    "modified": "(a) If the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter exceeds the Quarterly Maximum Details for such Calendar Quarter, then the promotion fee due under Section 6.1.1 will be subject to a deduction, with the Applicable Percentage for such Calendar Quarter being increased to a new percentage not less than [***].\n\nIn this revised clause, the original obligation (reducing the percentage if the number of Details is less than the Quarterly Minimum) has been weakened (deducting the promotion fee if the number of Details exceeds the Quarterly Maximum). Additionally, the responsibility for reducing the percentage has been shifted to increasing it under certain circumstances.",
    "contradiction_score": 0.5912998914718628,
    "kept": true
  },
  {
    "clause_index": 176,
    "start_char": 89553,
    "end_char": 92163,
    "original": "6.3.1  Quarterly Reports and Payments . Within [***] after the end of each Calendar Quarter during the Term, Dova shall provide to Valeant a written report setting forth in reasonable detail the calculation of the Net Sales for such Calendar Quarter and the promotion fee payable in respect of such Net Sales in accordance with Section 6.1, including (i) the number of units of the Product shipped from Specialty Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional writing the applicable prescription, (ii) the number of units of the Product shipped from Specialty Pharmacies to patients in the Territory based on prescriptions written by the Specialty only during such Calendar Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription (iii) the number of units per shipment of Products (and the number of such shipments) sold by Dova (or its Affiliates or Intermediaries) to the Non-Retail Institutions during such Calendar Quarter, including details respecting which shipments are based on initial orders from such Non-Retail Institutions and which Non-Retail Institutions ordered the Product, (iv) the number of units of the Product shipped from Retail Pharmacies to patients in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional writing the applicable prescription, (v) the number of units shipped from Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory during such Calendar Quarter, together with an itemized list of such units by Target Professional in the Specialty writing the applicable prescription, (vi) the applicable Specialty Fraction for such Calendar Quarter, (vii) the WAC applicable to each dispensable unit, (ix) the Gross to Net Fraction for the applicable period, together with the details respecting the calculation thereof (including details regarding each of the categories of the deductions to gross sales for such Calendar Quarter). Within sixty (60)  days after the end of each Calendar Quarter during the Term, Dova shall pay to Valeant the undisputed portion of the promotion fee payable in respect of such Net Sales in accordance with Section 6.1. If this Agreement terminates or expires during a Calendar Quarter, the promotion fee payable to Valeant under Section 6.1 will be calculated only on the Net Sales that occurred during such Calendar Quarter prior to the effective date of such termination or expiration.",
    "ollama_generated": "6.3.1 Quarterly Reports and Payments: Valeant shall receive, within [***] before the commencement of each new Calendar Quarter during the Term, a written report from Dova, containing a reasonable summary of the Net Sales for the preceding Calendar Quarter, as well as the applicable promotion fee in accordance with Section 6.1. The report shall include (i) the total number of units of the Product distributed to patients within the Territory through Specialty Pharmacies during the said quarter, listed by Target Professional responsible for the prescriptions, (ii) the number of units shipped from Specialty Pharmacies to patients within the Territory, based on prescriptions written exclusively by the Specialty during the same quarter, also itemized by Target Professional, (iii) the total number of units per shipment of Products (and the total number of such shipments) sold by Dova (or its Affiliates or Intermediaries) to Non-Retail Institutions during the said quarter, detailing initial orders and the identities of these institutions, (iv) the number of units of the Product shipped from Retail Pharmacies to patients within the Territory during the same quarter, again itemized by Target Professional responsible for the prescriptions, (v) the number of units shipped from Retail Pharmacies to patients based on prescriptions written by the Specialty in the Territory during the same quarter, with an additional listing of such units by Target Professional in the Specialty, (vi) the applicable Specialty Fraction for the quarter, (vii) the Wholesale Acquisition Cost (WAC) applicable to each dispensable unit, (ix) the Gross to Net Fraction for the relevant period, along with details regarding the calculation thereof (including information about each of the deductions to gross sales for the said quarter). Valeant shall be responsible for making any payments to Dova for the undisputed portion of the promotion fee payable in respect of such Net Sales within sixty (60) days following the end of each Calendar Quarter during the Term. If this Agreement terminates or expires during a Calendar Quarter, Valeant's entitlement to the promotion fee under Section 6.1 will be calculated based on the Net Sales that occurred during the entirety of such Calendar Quarter, including post-termination or expiration sales.",
    "contradiction_score": 0.24954625964164734,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 186,
    "start_char": 99135,
    "end_char": 101150,
    "original": "6.5.3  In the event that Dova\u2019s Third Party Data Source agrees to conduct such investigation, and then based on the results of such investigation, Dova\u2019s Third Party Data Source changes the primary designation of the Target Professional to Gastroenterology, Colorectal Surgery or Proctology or, in the case of those Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, confirms that the primary specialty designation should remain Gastroenterology, Colorectal Surgery or Proctology, then, commencing with the Calendar Quarter in which such investigations were conducted, such Target Professionals shall be deemed to be in the Specialty (regardless of whether their secondary specialty designation remains or becomes Hepatology). In the event that, following such investigation, Dova\u2019s Third Party Data source does not change the primary specialty designation to Gastroenterology, Colorectal Surgery or Proctology or, in the case of those Target Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation of Hepatology, changes the primary specialty designation to a specialty other than Gastroenterology, Colorectal Surgery or Proctology, then those Target Professionals shall be deemed not to be in the Specialty. For those Target Professionals that were not the subject of an inquiry to or an investigation by Dova\u2019s Third Party Data Source, then the specialty designations set out in the original list generated by Dova\u2019s Third Party Data Source shall apply for such Calendar Quarter, namely those Target Professionals that have either a Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 primary or a secondary specialty designation of Gastroenterology, Colorectal Surgery or Proctology and that do not have either a primary or a secondary specialty designation of Hepatology shall be deemed to be in the Specialty.",
    "modified": "6.5.3 If Dova's Third Party Data Source does not initiate an investigation or, if it does and subsequently maintains or changes the primary specialty designation of a Target Professional to anything other than Gastroenterology, Colorectal Surgery, Proctology, or for those with a primary specialty of these and a secondary specialty of Hepatology, changes the primary specialty designation to another field, such Target Professionals will not be considered within the Specialty for that Calendar Quarter. Conversely, if Dova's Third Party Data Source conducts an investigation and subsequently changes or maintains the primary specialty designation of a Target Professional to Gastroenterology, Colorectal Surgery, or Proctology (excluding those with a secondary specialty of Hepatology), or confirms that the primary specialty designation should remain these fields for Target Professionals with both primary and secondary specialties in these areas, such professionals will be deemed to be within the Specialty, regardless of any subsequent changes to their secondary specialty designation. For those Target Professionals not subjected to investigation by Dova's Third Party Data Source, the original specialty designations provided by Dova Pharmaceuticals Inc., as listed in its 10-Q filing of 11/8/2018, will apply for that Calendar Quarter. This includes those Target Professionals who have a primary or secondary specialty designation of Gastroenterology, Colorectal Surgery, or Proctology and do not have a primary or secondary specialty designation of Hepatology, and are thus deemed to be within the Specialty.",
    "contradiction_score": 0.9770405292510986,
    "kept": true
  },
  {
    "clause_index": 194,
    "start_char": 108349,
    "end_char": 109795,
    "original": "8.1.2  Dova Property . Subject to the terms of Section 8.1.1, Dova shall have and retain sole and exclusive right, title and interest in and to all inventions, developments, discoveries, writings, trade secrets, Know-How, methods, practices, procedures, designs, improvements and other technology, whether or not patentable or copyrightable, and any patent applications, patents, or copyrights based thereon (collectively, \u201c Intellectual Property \u201d) relating to the Product that are (i) owned or controlled by Dova as of the Effective Date, (ii) made, discovered, conceived, reduced to practice or generated by Dova (or its employees or representatives) during the Term, or (iii) made, discovered, conceived, reduced to practice or generated by Valeant (or its employees or representatives) in performing its activities pursuant to this Agreement to the extent primarily related to the Product or which is otherwise derived from the Confidential Information of Dova (\u201c Inventions \u201d). Valeant agrees to assign, and hereby does assign, to Dova (and shall cause its Affiliates and its and their respective employees and other representatives to assign to Dova) any and all right, title and interest that Valeant (or any such Affiliates, employees or other representatives) may have in or to any Invention. For clarity, any and all Inventions and any information contained therein or related thereto shall constitute Confidential Information of Dova.",
    "modified": "8.1.2 Dova Property. Subject to the terms of Section 8.1.1, Valeant shall grant, and hereby does grant, to Dova (and shall cause its Affiliates and their respective employees and other representatives to grant to Dova) any and all right, title, and interest that Valeant (or any such Affiliates, employees, or other representatives) may have in or to any Invention. This includes but is not limited to inventions, developments, discoveries, writings, trade secrets, Know-How, methods, practices, procedures, designs, improvements, and other technology relating to the Product that are (i) owned or controlled by Dova as of the Effective Date, (ii) made, discovered, conceived, reduced to practice, or generated by Dova (or its employees or representatives) during the Term, or (iii) made, discovered, conceived, reduced to practice, or generated by Valeant (or its employees or representatives) in performing its activities pursuant to this Agreement to the extent primarily unrelated to the Product. Any Inventions and any information contained therein or related thereto shall be considered Confidential Information of Valeant. For clarity, Dova agrees to take no ownership or control over any such Invention unless specifically agreed upon in writing by both parties.",
    "contradiction_score": 0.7882111668586731,
    "kept": true
  },
  {
    "clause_index": 196,
    "start_char": 110079,
    "end_char": 111042,
    "original": "8.3 Protection of Trademarks and Copyrights . As between the Parties, Dova shall have the sole right (but not the obligation), as determined by Dova in its sole discretion, to (i) maintain the Dova Trademarks and Copyrights and/or (ii) protect, enforce and defend the Dova Trademarks and Copyrights. Valeant shall give notice to Dova of any infringement of, or challenge to, the validity or enforceability of the Dova Trademarks and Copyrights promptly after learning of such infringement or challenge. If Dova institutes an action against Third Party infringers or takes action to defend the Dova Trademarks and Copyrights, Valeant shall reasonably cooperate with Dova, at Dova\u2019s cost and expense. Any recovery obtained by Dova as a result of such proceeding or other actions, whether obtained by settlement or otherwise, shall be retained by Dova. Valeant shall not have any right to institute any action to defend or enforce the Dova Trademarks and Copyrights.",
    "modified": "8.3 Trademark and Copyright Protection Responsibilities. While both Parties share responsibility for protecting the collective intellectual property, it is primarily Valeant's duty (but not obligation), as decided by Valeant at its discretion, to either maintain the Valeant Trademarks and Copyrights or take steps to safeguard, assert, and defend them. Dova will be promptly informed by Valeant of any infringement or challenge regarding the validity or enforceability of the Valeant Trademarks and Copyrights. Should Valeant initiate legal action against infringing Third Parties or take steps to protect the Valeant Trademarks and Copyrights, Dova is obliged to provide reasonable cooperation, at Valeant's expense. Any recovery gained from such proceedings or other actions, whether via settlement or otherwise, will be retained by Valeant. Dova retains the right to institute actions against infringers of the Valeant Trademarks and Copyrights.",
    "contradiction_score": 0.8096163868904114,
    "kept": true
  },
  {
    "clause_index": 203,
    "start_char": 115212,
    "end_char": 115644,
    "original": "Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party\u2019s Confidential Information pursuant to Section 9.1.2(a) or 9.1.2(c), such Party shall, if permitted, promptly notify the other Party of such required disclosure and shall use reasonable efforts to assist the other Party (at the other Party\u2019s cost) in obtaining, a protective order preventing or limiting the required disclosure.",
    "ollama_generated": "Contrariwise to the preceding stipulations, should it transpire that one Party is compelled to divulge the Confidential Information of the other Party under Section 9.1.2(a) or 9.1.2(c), such Party shall, if applicable, provide notice to the other Party without undue delay regarding this obligatory disclosure. However, it should be noted that this Party shall not bear any responsibility for securing a protective order preventing or limiting the disclosure, unless mutually agreed upon by both Parties, in which case the cost of such endeavor shall be borne by the Party seeking the protective order.",
    "contradiction_score": 0.06209827587008476,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 210,
    "start_char": 123999,
    "end_char": 124999,
    "original": "\u00a7 335a, (ii) exclusion, debarment, suspension or ineligibility to participate in the Federal health care programs or in Federal procurement or nonprocurement programs, (iii) convicted (or conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) listed (or listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) listed (or listing) on the General Services Administration\u2019s List of Parties Excluded from Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Dova shall immediately notify Valeant, and Valeant shall have the option to prohibit such Person from performing work relating to this Agreement or the Product\u037e and 10.1.15  any patient assistance program used in connection with the Product used in connection with the Product have each been operated in accordance with Applicable Law.",
    "modified": "\u00a7 335a (ii) exemption, eligibility, reinstatement, or permission to participate in Federal health care programs or in Federal procurement or nonprocurement programs, (iii) not convicted (or no conviction) of a criminal offense that falls within the ambit of the Federal statute providing for mandatory exclusion from participation in Federal healthcare programs, (iv) not listed (or no listing) on the HHS/OIG List of Excluded Individuals/Entities (available through the Internet at http://oig.hhs.gov) or (v) not listed (or no listing) on the General Services Administration\u2019s List of Parties Eligible for Federal Programs (available through the Internet at hhtp://epls.arnet.gov), Dova shall immediately notify Valeant, and Valeant shall not have the option to permit such Person from performing work relating to this Agreement or the Product; and 10.1.15 any patient assistance program used in connection with the Product used in connection with the Product have each been operated in violation of Applicable Law.\n\nThis revised clause weakens the original obligation by removing the option for Valeant to prohibit a Person from performing work under certain conditions, and instead, Valeant is now obligated not to permit such Person. Additionally, it shifts responsibility by stating that any patient assistance program used in connection with the Product must be operated in violation of Applicable Law, rather than in accordance with it as in the original clause.",
    "contradiction_score": 0.9370327591896057,
    "kept": true
  },
  {
    "clause_index": 213,
    "start_char": 130482,
    "end_char": 130515,
    "original": "PROPERTY RIGHTS OF THIRD PARTIES.",
    "ollama_generated": "THIRD-PARTY INTERFERENCE WITH PROPERTY RIGHTS.\n\nThe Owner shall not be liable for any claims arising from third parties interfering with or asserting rights over the Property, unless such third party can demonstrate that they have a valid and legally recognized claim to the Property under applicable law or this Agreement. The Owner reserves the right to take reasonable steps to protect its property rights in the event of such interference, but shall not be obligated to do so.",
    "contradiction_score": 0.3575420677661896,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 216,
    "start_char": 131504,
    "end_char": 131780,
    "original": "10.4.2  Third Party Agreements . Dova shall remain solely responsible for the payment of royalty, milestone and other payment obligations, if any, due to Third Parties on (or in connection with) the sale of Product in the Territory, including under the Third Party Agreements.",
    "modified": "10.4.2 Third Party Agreements: The Liability for the Payment of Royalties, Milestones, and Other Obligations Due to Third Parties in Connection with the Sale of the Product within the Territory, Arising from the Third Party Agreements, Shall Primarily Rest with Vendor, with Due Understanding That Vendors May Seek Indemnification from Dova for Such Payments.\n\nIn this revised clause, the responsibility for payment obligations due to third parties has been shifted from Dova to the Vendor (previously referred to as \"Dova\"). The vendor may also seek indemnification from Dova for such payments, implying that Dova could potentially reimburse the vendor for these third-party payments.",
    "contradiction_score": 0.9801751971244812,
    "kept": true
  },
  {
    "clause_index": 219,
    "start_char": 134120,
    "end_char": 134620,
    "original": "11.3  Indemnification Procedures . The Party seeking indemnification under Section 11.1 or 11.2, as applicable (the \u201cIndemnified Party \u201d) shall give prompt notice to the Party against whom indemnity is sought (the \u201c Indemnifying Party \u201d) of the assertion or commencement of any Claim in respect of which indemnity may be sought under Section 11.1 or 11.2, as applicable, and will provide the Indemnifying Party such information with respect thereto that the Indemnifying Party may reasonably request.",
    "modified": "11.3 Indemnification Obligations and Procedures . The Party anticipating indemnity under Section 11.1 or 11.2, as applicable (the \u201cIndemnified Party\u201d), shall, at their discretion, choose not to immediately disclose the assertion or commencement of any Claim in respect of which indemnity might be claimed under Section 11.1 or 11.2, as applicable, and may withhold information regarding such claims from the Party responsible for providing indemnity (the \u201c Indemnifying Party\u201d), unless specifically required to do so by law or court order. The Indemnified Party will, however, upon request by the Indemnifying Party, provide all available information about any relevant Claims as soon as practicable and within their legal bounds.",
    "contradiction_score": 0.8652315139770508,
    "kept": true
  },
  {
    "clause_index": 225,
    "start_char": 138151,
    "end_char": 140767,
    "original": "12.2.1  by a Party upon written notice to the other Party in the event of a material breach of this Agreement by such other Party where such breach is not cured (if able to be cured) within [***] following such other Party\u2019s receipt of written notice of such breach (and any such termination shall become effective at the end of such [***] period unless the breaching Party has cured such breach prior to the expiration of such [***] period)\u037e 12.2.2  by Dova if the Quarterly Average Sales Force Size is less than [***] Sales Representatives for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the Quarterly Average Sales Force Size is less than [***] Sales Representatives\u037e 12.2.3  by Dova if the aggregate actual number of Details for the Product made by the Sales Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for [***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to be delivered no less than [***] following the end of the last consecutive Calendar Quarter in which the actual Details are less than the Quarterly Minimum Details\u037e Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 12.2.4  by either Party upon [***] written notice to the other Party following the withdrawal of the Product from the market by Dova (or the decision by Dova to withdraw the Product from the market) due to (i) any decision, judgment, ruling or other requirement of the FDA, or (ii) material safety concern\u037e 12.2.5  by Dova upon [***] written notice to Valeant upon the cessation of marketing by Valeant of the Designated Product (or the Alternate Product in accordance with Section 4.2.1(c), as the case may be)\u037e 12.2.6  by Dova pursuant to Section 4.2.1(c)\u037e and 12.2.7  by a Party immediately upon written notice to the other Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to such other Party, or upon an assignment of a substantial portion of the assets for the benefit of creditors by such other Party, or in the event a receiver or custodian is appointed for such other Party\u2019s business or a substantial portion of such other Party\u2019s business is subject to attachment or similar process\u037e provided, however, in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the party consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof.",
    "ollama_generated": "12.2.1 Either Party may choose not to respond to a material breach of this Agreement by the other, without providing notice or remedy, and such non-response shall be considered as tacit acceptance of the breach. However, should either Party decide to respond within [***] following the breach, the offending party will have an opportunity to rectify the breach during a grace period of [***]. If the breach remains unrectified at the end of this period, this Agreement may be terminated.\n\n12.2.2 Dova may opt not to enforce the requirement that the Quarterly Average Sales Force Size exceeds [***] Sales Representatives for up to [***] consecutive Calendar Quarters. Notice of this decision shall be provided to Valeant no less than [***] following the end of the last quarter in question.\n\n12.2.3 Similarly, Dova may elect not to enforce the Quarterly Minimum Details requirement for up to [***] consecutive Calendar Quarters. Notice of this choice shall be given to Valeant no less than [***] following the end of the last quarter during which the requirements were not met.\n\n12.2.4 Either Party may choose to withdraw from this Agreement upon [***] written notice to the other, following the withdrawal of the Product from the market by Dova (or Dova's decision to withdraw the Product) due to (i) any decision, judgment, ruling or other requirement of the FDA, or (ii) a material safety concern.\n\n12.2.5 Dova may decide not to require Valeant to continue marketing the Designated Product (or Alternate Product, as applicable), upon [***] written notice to Valeant.\n\n12.2.6 Dova retains the option to cease this agreement in accordance with Section 4.2.1(c).\n\n12.2.7 Either Party may terminate this Agreement immediately upon written notice to the other, following the filing or institution of bankruptcy, reorganization, liquidation, receivership proceedings, assignment of a substantial portion of assets for creditors, appointment of a receiver or custodian for the business, or attachment or similar process against a substantial portion of the business. In the case of an involuntary bankruptcy proceeding, this right to terminate shall only become effective if the party does not consent to the proceeding or the proceeding is not dismissed within [***] after the filing thereof.",
    "contradiction_score": 0.34104132652282715,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 228,
    "start_char": 141062,
    "end_char": 141710,
    "original": "12.3.2  Either Party shall have the right to terminate this Agreement before the end of the Term upon [***] written notice to the other Party delivered within [***] after the conclusion of any Calendar Quarter, beginning with the Calendar Quarter commencing on [***], in which the Net Sales in such Calendar Quarter are less [***] (and any such termination shall become effective at the end of such [***] period)\u037e provided that Valeant shall not have the right to terminate this Agreement pursuant to this Section 12.3.2 with respect to any Calendar Quarter for which the Quarterly Average Sales Force Size is less than [***] Sales Representatives.",
    "ollama_generated": "12.3.2 Either Party shall retain the option, at their discretion, to extend this Agreement beyond the initial Term, by providing [***] written notice to the other Party no later than [***] prior to the commencement of any new Calendar Quarter. However, this extension right is contingent upon the condition that the Net Sales in the preceding Calendar Quarter have surpassed [***], and such extension shall take effect from the beginning of the subsequent Calendar Quarter if this requirement is met. Notably, Valeant shall be granted the ability to exercise this Section 12.3.2 with respect to any Calendar Quarter only when the Quarterly Average Sales Force Size exceeds [***] Sales Representatives.",
    "contradiction_score": 0.29490748047828674,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 233,
    "start_char": 145880,
    "end_char": 147448,
    "original": "13.2  Assignment . Except as provided in this Section 13.2, this Agreement may not be assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned or transferred, by either Party, without the written consent of the other Party (such consent not to be unreasonably withheld)\u037e provided that a merger, sale of stock or comparable transaction shall not constitute an assignment. In the event either Party desires to make such an assignment or other transfer of this Agreement or any rights or obligations hereunder, such Party shall deliver a written notice to the other Party requesting the other Party\u2019s written consent in accordance with this Section 13.2, and the other Party shall provide such Party written notice of its determination whether to provide such written consent within [***] following its receipt of such written notice from such Party. Notwithstanding the foregoing, (a) either Party may, without the other Party\u2019s consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate\u037e and (b) Dova may assign this Agreement to a successor in interest in connection with the sale or other transfer of all or substantially all of Dova\u2019s assets or rights relating to the Product\u037e provided that such assignee shall remain subject to all of the terms and conditions hereof in all respects and shall assume all obligations of Dova hereunder whether accruing before or after such assignment. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement.",
    "modified": "13.2 Assignment: Save for the instances detailed within this Section 13.2, neither Party has the right to assign or transfer this Agreement, nor may they delegate their duties, without obtaining the prior, written consent of the other Party (such consent not to be unreasonably withheld). However, a merger, sale of stock, or similar transaction shall not be considered as an assignment. Should either Party choose to transfer this Agreement or any rights and obligations herein, they must provide written notice to the other Party requesting approval in accordance with this Section 13.2. The receiving Party will respond within [***] days, indicating whether they grant or deny consent.\n\nIn contrast, either Party may, without the need for prior consent from the other, assign this Agreement and its corresponding rights and obligations to any Affiliate. Additionally, Dova is authorized to transfer this Agreement to a successor in interest, contingent upon the sale or transfer of all or most of Dova's assets or rights pertaining to the Product. The recipient of such an assignment shall be bound by all terms and conditions stipulated herein, assuming obligations previously held by Dova, whether accrued before or after the assignment. Any permitted assignee shall assume all assigned obligations of their assignor under this Agreement.",
    "contradiction_score": 0.7044077515602112,
    "kept": true
  },
  {
    "clause_index": 241,
    "start_char": 149149,
    "end_char": 149677,
    "original": "XXXXXXXX Attention: XXXXXXXX Fax: XXXXXXXX Email: XXXXXXXX or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered\u037e (b) on the Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 Business Day after dispatch if sent by nationally-recognized overnight courier\u037e or (c) on the fifth (5th) Business Day following the date of mailing, if sent by mail.",
    "ollama_generated": "Notice Attention: Notifying Party's Contact Details: [Specify notifying party's contact details] Alternatively, any updated contact information provided in accordance with this agreement shall be valid for notice purposes. Any such notice shall be considered effectively delivered as follows: (a) upon personal delivery; (b) on the next Business Day following dispatch if sent by a reputable international courier service; or (c) on the tenth (10th) Business Day following the mailing date, if sent via postal service.\n\nThis revision shifts the responsibility for providing updated contact information to the party receiving notice and extends the timeframe for delivery by courier and mail.",
    "contradiction_score": 0.008706607855856419,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 250,
    "start_char": 153308,
    "end_char": 153610,
    "original": "13.11  Third Party Beneficiaries . Except as set forth in ARTICLE 11, no Person other than Dova or Valeant (and their respective Affiliates and permitted successors and assignees hereunder) shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.",
    "ollama_generated": "13.11 Third Party Rights and Enforcement: Only Dova and Valeant (alongside their respective Affiliates, permissible successors, and assigns under the terms of this Agreement) are expressly intended to benefit from this Agreement, and no other party shall possess the right to enforce any provision herein.",
    "contradiction_score": 0.008812807500362396,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 264,
    "start_char": 159746,
    "end_char": 161031,
    "original": "\u201cWe are delighted to be working with Salix, a company considered by many to have the preeminent gastroenterology sales force in the United States,\u201d said Alex C. Sapir, president and chief executive officer, Dova Pharmaceuticals. \u201cGiven Salix\u2019s presence and strong reputation within large gastroenterology group practices coupled with the early interest we are seeing among the gastroenterology community, we are excited to see the impact this partnership will bring to DOPTELET and to patients.\u201d \u201cSalix considers liver disease a strategic therapeutic area of focus, given our history and knowledge with XIFAXAN\u00ae (rifaximin), an innovative medicine indicated for the treatment of overt hepatic encephalopathy (HE), a condition that is often a consequence of chronic liver disease,\u201d said Mark McKenna, president, Salix Pharmaceuticals. \u201cAdding DOPTELET to our portfolio will enable our sales force to promote yet another innovative product that addresses a true unmet need in the marketplace.\u201d CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "ollama_generated": "\"We are pleased to be collaborating with Salix, a company widely recognized as having a leading gastroenterology sales force in the United States,\" remarked Alex C. Sapir, president and chief executive officer, Dova Pharmaceuticals. \"While we acknowledge Salix's significant presence and esteemed reputation within large gastroenterology group practices, our anticipation lies not only in their influence but also in the potential response from the gastroenterology community. We eagerly look forward to the effects this partnership will have on DOPTELET and the patients it serves.\"\n\n\"Salix identifies liver disease as a strategic therapeutic area of emphasis, leveraging our past experience and insights with XIFAXAN\u00ae (rifaximin), a pioneering medication approved for treating overt hepatic encephalopathy (HE), a condition frequently associated with chronic liver disease,\" said Mark McKenna, president, Salix Pharmaceuticals. \"The addition of DOPTELET to our product lineup will empower our sales team to advocate for another groundbreaking treatment that addresses a persisting demand in the medical marketplace.\"\n\nCONFIDENTIAL INFORMATION HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH REMOVES THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE MARKED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN DEPOSITED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\"\n\nIn this revised clause, the meaning has been slightly altered by changing the tone from excitement to anticipation and placing more emphasis on the potential response from the gastroenterology community. Additionally, the wording of Salix's strategic focus on liver disease has been rephrased to imply a stronger commitment. The confidentiality request remains intact, but the filing with the Securities and Exchange Commission is emphasized.",
    "contradiction_score": 0.11063022166490555,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 267,
    "start_char": 162144,
    "end_char": 163091,
    "original": "23%, p <0.0001\u037e ADAPT-2, 69% vs. 35%\u037e p=0.0006) treatment groups. Avatrombopag was also superior to placebo at the two secondary efficacy endpoints in each trial. In the avatrombopag treatment groups, there was an increased proportion of patients achieving the target platelet count of \u226550,000/\u00b5mL on procedure day, and a greater magnitude of the change in mean platelet count from baseline to procedure day\u037e all treatment differences between the avatrombopag and placebo treatment groups for each secondary endpoint were highly statistically significant with p values <0.0001. The most common adverse reactions with avatrombopag included pyrexia, abdominal pain, nausea, headache, fatigue and edema peripheral. Portal vein thromboses have been reported in patients with CLD and in patients receiving TPO receptor agonists. One treatment-emergent event of portal vein thrombosis was reported in the ADAPT trials in an avatrombopag-treated patient.",
    "ollama_generated": "23%, p <0.0001; ADAPT-2, 69% vs. 35% (p=0.0006) - This suggests that patients in the avatrombopag treatment groups experienced a more significant improvement compared to those on placebo, albeit with a lower baseline response rate for the control group. Avatrombopag demonstrated superiority over placebo at the two secondary efficacy endpoints across both trials. Significantly higher proportions of patients in the avatrombopag treatment groups achieved the target platelet count of \u226550,000/\u00b5mL on procedure day, and the improvement in mean platelet count from baseline to procedure day was also greater for those receiving avatrombopag. All treatment differences between the avatrombopag and placebo treatment groups for each secondary endpoint were highly statistically significant with p values <0.0001.\n\nCommon adverse reactions associated with avatrombopag use include pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral. It is noteworthy that portal vein thromboses have been reported in patients with Chronic Liver Disease (CLD) and those receiving Thrombopoietin receptor agonists. Importantly, one case of treatment-emergent event of portal vein thrombosis was reported in the ADAPT trials involving an avatrombopag-treated patient, underscoring the need for vigilance when administering this medication.",
    "contradiction_score": 0.00840979814529419,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 268,
    "start_char": 163091,
    "end_char": 163263,
    "original": "INDICATION DOPTELET (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.",
    "ollama_generated": "The administration of INDICATION DOPTELET (avatrombopag) is suggested for adult patients with chronic liver disease, particularly when such individuals find themselves preparing for a medical procedure, aiming to address any potential thrombocytopenia that may arise during or post-procedure.",
    "contradiction_score": 0.0015977181028574705,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 273,
    "start_char": 164544,
    "end_char": 164729,
    "original": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 ADVERSE REACTIONS Most common adverse reactions (\u2265 3%) were: pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.",
    "ollama_generated": "DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018 - ADVERSE REACTIONS\nThe following represent the most frequent adverse reactions (observed in at least 3% of cases): fever (pyrexia), abdominal discomfort, vomiting (nausea), headaches, lethargy (fatigue), and swelling in extremities (edema peripheral).",
    "contradiction_score": 0.0013564468827098608,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 275,
    "start_char": 165094,
    "end_char": 165273,
    "original": "*There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.",
    "ollama_generated": "The use of XIFAXAN may pose a heightened risk in patients presenting with advanced (Child-Pugh Class C) liver dysfunction, necessitating careful consideration before administration. It is strongly advised that medical professionals exercise prudence when prescribing this drug to such patients.",
    "contradiction_score": 0.000391152425436303,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 278,
    "start_char": 165719,
    "end_char": 165846,
    "original": "\u2022If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (C.",
    "ollama_generated": "\u2022Should the use of antibiotics, particularly XIFAXAN, occur, it's possible that you may develop diarrhea as a result of bacterial overgrowth (C.). We advise you to consult a healthcare professional if this symptom arises.",
    "contradiction_score": 0.0005072577623650432,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 289,
    "start_char": 167898,
    "end_char": 167930,
    "original": "About Dova Pharmaceuticals, Inc.",
    "ollama_generated": "Regarding Dova Pharmaceuticals, Inc.:\n\nIn the event of any discrepancies or misunderstandings arising between the parties concerning this agreement, it shall be incumbent upon the other party to Dova Pharmaceuticals, Inc. to rectify and clarify such matters expeditiously, in a manner that does not conflict with Dova's core objectives or business practices. Failure to do so shall render the other party free from any obligation stipulated herein, unless otherwise specified. This provision is intended to provide Dova Pharmaceuticals, Inc. with a degree of flexibility in addressing issues that may arise under this agreement.",
    "contradiction_score": 0.020311638712882996,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 295,
    "start_char": 170810,
    "end_char": 171232,
    "original": "Any forward-looking statements speak only as of the date of this press release and are based on information available to Dova as CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "ollama_generated": "Any forward-looking statements provided in this press release represent our views as of the date of this document, and are predicated on the information known to us at that time. It is important to note that future events or developments may cause our actual results to differ materially from these statements. We assume no obligation to update any forward-looking statements, except as required by law. Confidential portions of this exhibit have been omitted and designated [***] in accordance with a confidentiality request. A complete version of this exhibit, including the omitted information, has been separately filed with the Securities and Exchange Commission.",
    "contradiction_score": 0.31749647855758667,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 300,
    "start_char": 173279,
    "end_char": 173369,
    "original": "Mark W. Hahn Chief Financial Officer mhahn@dova.com (919) 338-7936 Salix Investor Contact:",
    "ollama_generated": "Mark W. Hahn serves as the Investor Liaison, with the email address mhahn@dova.com and phone number (919) 338-7936. The role of the Investor Contact is to facilitate communications with Salix Pharmaceuticals regarding any investment inquiries or updates.\n\nIn this capacity, Mark Hahn shall endeavor to respond promptly and effectively to all such inquiries, but assumes no liability for any delays or failures in communication arising from unforeseen circumstances beyond his control. The ultimate responsibility for the accuracy and completeness of information conveyed lies with Salix Pharmaceuticals.",
    "contradiction_score": 0.0022628572769463062,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 307,
    "start_char": 174900,
    "end_char": 174999,
    "original": "2.License Agreement dated August 15, 2005 (as amended) between Astellas Pharma Inc. and AkaRx, Inc.",
    "ollama_generated": "2. As of August 15, 2005 (with subsequent amendments), the Licensing Agreement exists between AkaRx, Inc. and Astellas Pharma Inc., with the implied understanding that any obligations or responsibilities arising therefrom are primarily the responsibility of Astellas Pharma Inc.\n\nIn this revised clause, the focus shifts from Astellas Pharma Inc. being the initial party to the Licensing Agreement (as in the original) to AkaRx, Inc., while also implying that most obligations or responsibilities stemming from the agreement fall on Astellas Pharma Inc. This change subtly weakens the obligations of AkaRx, Inc. and shifts more responsibility onto Astellas Pharma Inc.",
    "contradiction_score": 0.017857735976576805,
    "kept": false,
    "reason": "low_contradiction"
  }
]